Reconstruction of the arteries through surgery is the primary treatment, but drug-eluting stents
could offer a less invasive option.
Our results clearly show that drug-eluting stents
are indeed safe," said Pamela Douglas, M.
A 49-year-old male was scheduled for colonoscopy 630 days after having a paclitaxel drug-eluting stent
inserted in his right coronary artery for management of an inferior myocardial infarction.
the two FDA-approved drug-eluting stents
, when used for on-label indications, are reasonably sate and effective," Bram Zuckerman, director of CDRH's cardiovascular device review division, told
It is completely unclear how cardiologists should manage restenosis within a drug-eluting stent
Forthe study, researchers examined 80 patients, roughly half of whom had vein grafts with drug-eluting stents
and the other half who had the same procedure with bare-metal stents.
Two brands of drug-eluting stents
, Cypher and Taxus, currently compete in the U.
Receives Approval for its Drug-Eluting Stent
, "Endeavor" In Canada II-38 Boston Scientific to Market TAXUS[R] Liberte[R] Stent System in Canada II-38 Abbott Applies for Approval of XIENCE[TM] V in Japan II-38 Medinol Achieves CE Mark Approval for Presillion[TM] Cobalt Chromium Coronary Stent System II-39 Iberhospitex Receives Spanish Approval to Sell Palau Pharma's "Active" Coronary Stent II-39 Clearstream's Intrepide Drug Eluting Stent of Clearstream Receives CE mark approval II-39 Terumo Introduces Its Drug-Eluting Stent
in Germany and Marks Its European Entry II-39 Tryton Medical's Side-Branch Stent Achieves CE Mark Approval II-39 CV Therapeutics Offers its Stent Coating Technology to Medlogics Device Corporation II-40 Abbott's 2.
Predictions that drug-eluting stents
will prove harmful in the long run do us all an injustice by impairing the development of this important new treatment.
It makes sense to change coatings if a patient didn't respond to a drug-eluting stent
the first time," Dr.
In March 2007, Medtronic released two-year results from the largest and longest drug-eluting stent
clinical trial program to date.
6% rate of target-lesion revascularization with the drug-eluting stent
, compared with a 12.